CN111358940A - 一种疤痕祛除与防控组合液的应用 - Google Patents
一种疤痕祛除与防控组合液的应用 Download PDFInfo
- Publication number
- CN111358940A CN111358940A CN202010405123.9A CN202010405123A CN111358940A CN 111358940 A CN111358940 A CN 111358940A CN 202010405123 A CN202010405123 A CN 202010405123A CN 111358940 A CN111358940 A CN 111358940A
- Authority
- CN
- China
- Prior art keywords
- parts
- scar
- liquid
- scars
- mixed liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 105
- 239000007788 liquid Substances 0.000 title claims abstract description 86
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 42
- 230000037387 scars Effects 0.000 claims abstract description 42
- 230000001737 promoting effect Effects 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 14
- 102000008186 Collagen Human genes 0.000 claims abstract description 12
- 108010035532 Collagen Proteins 0.000 claims abstract description 12
- 229920001436 collagen Polymers 0.000 claims abstract description 12
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000008929 regeneration Effects 0.000 claims abstract description 9
- 238000011069 regeneration method Methods 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 230000017531 blood circulation Effects 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 230000003213 activating effect Effects 0.000 claims abstract description 7
- 230000000249 desinfective effect Effects 0.000 claims abstract description 6
- 230000003467 diminishing effect Effects 0.000 claims abstract description 6
- 238000002844 melting Methods 0.000 claims abstract description 6
- 230000008018 melting Effects 0.000 claims abstract description 6
- 238000011084 recovery Methods 0.000 claims abstract description 6
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 6
- 239000011259 mixed solution Substances 0.000 claims description 31
- 238000001914 filtration Methods 0.000 claims description 18
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 244000061520 Angelica archangelica Species 0.000 claims description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 12
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 9
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 9
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 9
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 9
- 244000097577 Rhus javanica Species 0.000 claims description 9
- 235000010889 Rhus javanica Nutrition 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 229940100243 oleanolic acid Drugs 0.000 claims description 9
- 229940072113 onion extract Drugs 0.000 claims description 9
- 229920001296 polysiloxane Polymers 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 8
- 244000235603 Acacia catechu Species 0.000 claims description 8
- 235000006226 Areca catechu Nutrition 0.000 claims description 8
- 102000016943 Muramidase Human genes 0.000 claims description 8
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 108010039918 Polylysine Proteins 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 8
- 241000258920 Chilopoda Species 0.000 claims description 7
- 241000244987 Daiswa polyphylla Species 0.000 claims description 7
- 241001313857 Bletilla striata Species 0.000 claims description 6
- 240000004824 Trimezia steyermarkii Species 0.000 claims description 6
- 239000009136 dragon's blood Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 241001609368 Acamptopappus Species 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 241000213006 Angelica dahurica Species 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000167550 Centella Species 0.000 claims description 2
- 241001290529 Kyllinga clade Species 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000009286 sanguis draxonis Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000035876 healing Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 4
- 102000009123 Fibrin Human genes 0.000 abstract description 3
- 108010073385 Fibrin Proteins 0.000 abstract description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract description 3
- 229950003499 fibrin Drugs 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 206010052428 Wound Diseases 0.000 description 24
- 238000000034 method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 230000036573 scar formation Effects 0.000 description 4
- 244000146462 Centella asiatica Species 0.000 description 3
- 235000004032 Centella asiatica Nutrition 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种疤痕祛除与防控组合液的应用,该组合液用于拟制疤痕的产生和祛除疤痕,该组合液包括用于活血化瘀、融化分解疤体组织的混合液I、用于消毒消炎、收敛生肌的混合液III以及用于激活毛细血管恢复、促进胶原新生的混合液III。本发明能够实现祛疤与防疤两策并举,双管齐下,标本兼治;一方面,在祛除上具有靶向性强、力猛的特点,其软化、缩小、平复疤痕效果都要比传统的祛疤产品明显,另一方面,抑制正在形成疤痕创口纤维蛋白的过度增生,促使组织有序生长,促进伤口愈合,且有效的控制疤痕产生。
Description
技术领域
本发明属于疤痕防治技术领域,尤其涉及一种疤痕祛除与防控组合液的应用。
背景技术
疤痕谁都不想有,但意外总是不经意就降临了。疤痕是代表皮肤曾受到创伤后的痕迹,丑陋的疤痕不仅影响到美好的形象、外在的颜值,还展示了过去的一段痛苦的经历。疤痕的存在也给许多人带来了困扰,尤其是年轻女性,怎样去除难看的疤痕,让人重获自信是疤痕一族非常关心的问题。有些“疤痕”还会给患者带来的是巨大的肉体痛苦和精神折磨,尤其是烧伤、烫伤、严重外伤后遗留的疤痕,若不幸产生疤痕挛缩,更会进一步影响四肢关节活动或五官的正常功能,这些疤痕更是非积极修复不可。
从疤痕形成的机理过程看,疤痕形成大约是从第3天开始从伤口底部及边缘长出肉芽组织填平伤口。毛细血管大约以每日延长0.1-0.6mm的速度增长。第5-6天起成纤维细胞产生胶原纤维,随着胶原纤维越来越多,出现瘢痕形成过程,大约在伤后一个月疤痕完全形成。由此可见,疤痕的形成是由于创面在愈合的过程中缺乏调控机制及愈合的皮肤缺乏保护。
因此,要从本质上解决疤痕问题,必须从防控着手,预防是最好的治疗,防疤就是在皮肤新创后,快速抑制疤痕的胶原纤维过度增殖,促使组织有序生长,创面在短期内愈合的恰到好处,加速创面愈合的同时,又避免了创面出现高低不平、潮红充血、质地坚韧、瘙痒灼痛、不规则的疤痕。
目前,非手术(包括植皮、激光以及封闭、打磨、填充治疗等)祛疤手段进行修复的产品层出不穷,种类繁多,但良莠不齐,甚至有违禁添加。存在问题是能减轻症状,但不易痊愈,剂型与功效单一,色沉严重,抗菌消炎效果差、防疤控疤效果弱等问题。
发明内容
为了解决现有技术中存在的问题,本发明的目的是提供一种疤痕祛除与防控组合液的应用,本发明能够实现祛疤与防疤两策并举,双管齐下,标本兼治;一方面,在祛除上具有靶向性强、力猛的特点,其软化、缩小、平复疤痕效果都要比传统的祛疤产品明显,另一方面,抑制正在形成疤痕创口纤维蛋白的过度增生,促使组织有序生长,促进伤口愈合,且有效的控制疤痕产生。
一种疤痕祛除与防控组合液的应用,该组合液用于拟制疤痕的产生和祛除疤痕,该组合液包括用于活血化瘀、融化分解疤体组织的混合液I、用于消毒消炎、收敛生肌的混合液II以及用于激活毛细血管恢复、促进胶原新生的混合液III;其中,
所述的混合液I,按重量份数计有以下各组分组成:
齐敦果酸20~40份、昆布20~40份、五倍子20~40份、金头蜈蚣5~10份、当归20~40份、鸦胆子油5~8份、硅酮5~10份、洋葱提取物7份;
所述的混合液II,按重量份数计有以下各组分组成:
积雪草提取物20~30份、七叶一枝花15~30份、昆布25~40份、五倍子10~15份、儿茶5~10份、白芨8~12份、当归5~10份、血竭3~6份;
所述的混合液III,按重量份数计有以下各组分组成:
ε-聚赖氨酸10~20份、溶菌酶20~40份、聚乙烯醇5~10份、醋酸氯已定3~5份。
进一步的,所述的混合液I的制备方法如下:
按照重量配比分别称取昆布、五倍子、金头蜈蚣和当归后,经粉碎、过筛、洗霉,然后倒入反应釜加入去离子水浸泡3小时,煮沸并恒温90℃,5小时,冷却、过滤,然后进行熬制3小时,冷却、过滤后得滤液,向滤液内加入齐敦果酸、鸦胆子油、硅酮和洋葱提取物,混合搅拌至完全溶解,将所得药液静置、再次过滤后,制得混合液I。
进一步的,所述的混合液II的制备方法如下:
按照重量配比分别称取积雪草提取物、七叶一枝花、昆布、五倍子、儿茶、白芨、当归及血竭,分别经粉碎、过筛、洗霉,倒入不锈钢容器,加入无水酒精,浸泡24×7小时,萃取液过滤,将所得药液静置、再次过滤后,制得混合液II。
进一步的,所述的混合液III的制备方法如下:
按照重量配比分别称取ε-聚赖氨酸、溶菌酶、聚乙烯醇和醋酸氯已定,倒入配置有搅拌机构的反应釜,开启搅拌,在倒入各组分时,边搅拌边加入原料,升温至50℃,恒温搅拌1小时,冷却将所得药液静置、过滤,制得混合液III。
进一步的,先使用混合液I涂抹于疤痕上,一天涂抹1-3次,涂抹数天,当疤痕出现发黑、结痂等终点反应后,使用混合液II和混合液III交替涂抹,直至创面愈合。
在本发明中,齐敦果酸,具有渗透性强;昆布、五倍子、金头蜈蚣、当归、鸦胆子油具有软坚散结、活血化瘀的功效,有较强穿透性;积雪草提取物,有抗炎、抗菌、抑制纤维组织增生,对瘢痕、妊娠纹都有很强的治疗作用的;硅酮,具有预防疤痕形成的功效,有静电场诱导作用,可使胶原重新排列,促进局部血液循环,增强角质组织的水合作用,增加皮肤保水度,改善细胞生长的微环境,让肌肤充满弹性,使疤痕组织保持湿润,软化变细;洋葱提取物,有消炎、杀菌、促进伤口愈合的作用。
与现有技术相比,本发明具有以下有益效果:
1、本发明的混合液I主要作用是软坚、散结、剥脱、分解、溶解,是安全的软化剂与弱效浸蚀剥脱剂,由外向内逐层渗透、软化、分解疤痕组织。它不仅具有活血化瘀、清热滋阴等功能,祛疤见效快、痊愈后无毒副作用等优点,还可以增强皮肤免疫力,抑制细菌生长。
2、本发明的混合液II主要作用是强大的消毒、抗炎、止痛、收敛、修复、生肌作用,加速疤痕的新陈代谢,去腐生新,用于疤痕治疗的修复期的消毒、止痛、生肌,对激光术后,烧烫伤后修复、止痛效果很好,同时对影响皮肤健康的化脓性球菌如炭疽杆菌、甲型及异型溶血性链球菌、白喉杆菌、类白喉杆菌、肺炎双球菌、金黄色葡萄球菌、柠檬色葡萄球菌、白色葡萄球菌及枯草杆菌、大肠杆菌、真菌如白色念珠菌等致病菌具有较强的抗菌抑菌作用。
3、本发明的混合液III的主要功效是抑制正在形成疤痕创口纤维蛋白的过度增生,促使组织有序生长、促进胶原新生、使伤口快速修复愈合的能力
4、本发明通过混合液I、混合液II、混合液III的协同作用,即先通过混合液I的外向内逐层渗透、软化、分解疤痕组织,而在混合液I的作用下,疤痕在分解过程中容易产生痒、痛等,然后使用混合液II,混合液II具有较强的抗菌抑菌以及止痛作用,使得患者在治疗中较有较好的舒适感,最后再使用混合液III,促使组织有序生长,促进胶原新生,快速修复愈合;通过混合液I、混合液II、混合液III的协同作用,使得本发明是控疤防疤、溶疤平复、抗炎消肿的一个闭环循环过程,具有疗程短、疗效好、费用低的特点。
具体实施方式
下面结合具体的实施例对本发明的技术方案做进一步详细的说明。
实施例1
一种疤痕祛除与防控组合液的应用,该组合液用于拟制疤痕的产生和祛除疤痕,该组合液包括用于活血化瘀、融化分解疤体组织的混合液I、用于消毒消炎、收敛生肌的混合液II以及用于激活毛细血管恢复、促进胶原新生的混合液III;其中,
所述的混合液I,按重量份数计有以下各组分组成:齐敦果酸20份、昆布20份、五倍子20份、金头蜈蚣5份、当归20份、鸦胆子油5份、硅酮5份、洋葱提取物7份;
所述的混合液II,按重量份数计有以下各组分组成:积雪草提取物20份、七叶一枝花15份、昆布25份、五倍子10份、儿茶5份、白芨8份、当归5份、血竭3份;
所述的混合液III,按重量份数计有以下各组分组成:ε-聚赖氨酸10份、溶菌酶20份、聚乙烯醇5份、醋酸氯已定3份。
实施例2
一种疤痕祛除与防控组合液的应用,该组合液用于拟制疤痕的产生和祛除疤痕,该组合液包括用于活血化瘀、融化分解疤体组织的混合液I、用于消毒消炎、收敛生肌的混合液II以及用于激活毛细血管恢复、促进胶原新生的混合液III;其中,
所述的混合液I,按重量份数计有以下各组分组成:齐敦果酸30份、昆布30份、五倍子30份、金头蜈蚣8份、当归30份、鸦胆子油6份、硅酮8份、洋葱提取物7份;
所述的混合液II,按重量份数计有以下各组分组成:积雪草提取物25份、七叶一枝花23份、昆布35份、五倍子12份、儿茶8份、白芨10份、当归8份、血竭4份;
所述的混合液III,按重量份数计有以下各组分组成:ε-聚赖氨酸15份、溶菌酶30份、聚乙烯醇8份、醋酸氯已定4份。
实施例3
一种疤痕祛除与防控组合液的应用,该组合液用于拟制疤痕的产生和祛除疤痕,该组合液包括用于活血化瘀、融化分解疤体组织的混合液I、用于消毒消炎、收敛生肌的混合液II以及用于激活毛细血管恢复、促进胶原新生的混合液III;其中,
所述的混合液I,按重量份数计有以下各组分组成:齐敦果酸40份、昆布40份、五倍子40份、金头蜈蚣10份、当归40份、鸦胆子油8份、硅酮10份、洋葱提取物7份;
所述的混合液II,按重量份数计有以下各组分组成:积雪草提取物30份、七叶一枝花30份、昆布40份、五倍子15份、儿茶10份、白芨12份、当归10份、血竭6份;
所述的混合液III,按重量份数计有以下各组分组成:ε-聚赖氨酸20份、溶菌酶40份、聚乙烯醇10份、醋酸氯已定5份。
在实施例1、2、3中,混合液I、混合液II、混合液III的制备方法分别如下:
所述的混合液I的制备方法如下:按照重量配比分别称取昆布、五倍子、金头蜈蚣和当归后,经粉碎、过筛、洗霉,然后倒入反应釜加入去离子水浸泡3小时,煮沸并恒温90℃,5小时,冷却、过滤,然后进行熬制3小时,冷却、过滤后得滤液,向滤液内加入齐敦果酸、鸦胆子油、硅酮和洋葱提取物,混合搅拌至完全溶解,将所得药液静置、再次过滤后,制得混合液I。
所述的混合液II的制备方法如下:按照重量配比分别称取积雪草提取物、七叶一枝花、昆布、五倍子、儿茶、白芨、当归及血竭,分别经粉碎、过筛、洗霉,倒入不锈钢容器,加入无水酒精,浸泡24×7小时,萃取液过滤,将所得药液静置、再次过滤后,制得混合液II。
所述的混合液III的制备方法如下:按照重量配比分别称取ε-聚赖氨酸、溶菌酶、聚乙烯醇和醋酸氯已定,倒入配置有搅拌机构的反应釜,开启搅拌,在倒入各组分时,边搅拌边加入原料,升温至50℃,恒温搅拌1小时,冷却将所得药液静置、过滤,制得混合液III。
本发明的应用为:先使用混合液I涂抹于疤痕上,一天涂抹1-3次,涂抹数天,当疤痕出现发黑、结痂等终点反应后,使用混合液II和混合液III交替涂抹,直至创面愈合。
本发明能够实现祛疤和疤痕防控双重效果,祛疤过程分为两个程序,即:剥脱程序和修复程序,具体来说,剥脱程序:混合液I涂抹于疤痕上,当疤痕出现发黑、结痂等终点反应后进入修复程序;修复程序:使用混合液II和混合液III交替涂抹,直至创面愈合;疤痕防控是针对新创伤的伤口,防止伤口后期形成疤痕,其应用过程为:使用混合液II和混合液III交替涂抹,直至创面愈合。
本发明在应用时,先使用混合液I,可以用小刷子或棉签,一天1-3次涂刷于疤痕上,注意不要流到正常皮肤上;也可以用略小于疤痕的单层纱布、棉片等,浸满药液后湿敷10-20分钟,不要浸得太饱,以免流到正常皮肤上,此方法特别适合于小而光滑的疤痕;对于细小凹坑,小刷子容易侵犯到正常皮肤,建议使用棉签棒或牙签,可适当削一下,先用竹棍在疤痕凹坑的底部及边缘磨、刮、钻等,损伤角质层,让药物可以更好的吸收,然后摆好体位,让疤痕凹坑水平,蘸上混合液I,灌满凹坑,待其吸收,点药后皮损处会变白,如果反应较轻可以重复一遍。
可以用0.25或0.3mm的滚针或电动微针(1mm以下深度)导入,做的时候不能过深,不能有破皮,以局部潮红,无出血为度,否则搽混合液I上去很痛。
滚针或微针治疗过重,用了混合液I后表皮很快出现溃烂、结痂,给人感觉已经达到终点反应了,如果此时开始修复,粘连、增生未得到有效软化、浸蚀与剥脱,修复出来的效果较差可以用纳晶的高针对需要治疗部位用点压手法进行刺激,每个部位点压3下,每次1秒钟,然后涂上混合液I。
混合液I在使用时,应注意:
使用频率:一天2-3次,一次2-3遍;
用量原则:3天出现中药色,7天软化出效果,否则检讨用法用量;
终点反应:疤痕发黑、干裂、糜烂、溃烂,水疱,结痂等停止使用混合液I,进入修复程序。
在使用混合液I的整个过程中,根据实际皮肤的反应程度,涂抹适宜次数的混合液II,混合液II具有较强的抗炎、止痛效果,混合液II使用酒精萃取,含有收敛因子,所以伤口上涂上去短时间很痛,但是里面有很强的消肿镇痛的作用的七叶一枝花很快发挥作用,使得疤痕在到达终点反应前,大大降低疤痕处的痛、痒的感觉。
为了进一步验证本发明的实际使用效果,进行人群试用,选择50名因座疮感染、烧伤、烫伤、创伤或手术后创面愈合形成有老疤痕的患者,年龄15-60岁,作为试验组1,选择50名新创伤尚未形成的疤痕的患者,年龄15-60岁,作为试验组2,对试验组1和试验组2的患者同时使用本发明中的组合液,每日早、晚2次涂抹或导入于疤痕上,试用1个月,统计结果如下表:
治愈/例 | 有效/例 | 无效/例 | 有效率/例 | |
新创伤 | 35 | 15 | 0 | 100% |
老疤痕 | 25 | 20 | 5 | 90% |
分级判定的标准:
治愈:新伤口愈合迅速,愈合皮肤表面光滑、柔软,老疤痕色泽变浅 ,硬度消失 ,与正常皮肤无分界模糊 ,自觉症状明显缓解。
有效:新伤口愈合迅速,愈合后表面稍留浅印痕,老疤痕色泽变浅 ,疤痕硬度变软,自觉症状明显缓解。
无效:无改变或症状加重。
由上表数据可知 ,老疤痕受试者使用本发明的组合液一个月,有效改善症状可达90%,新创伤受试者,有效改善症状可达100%。
Claims (4)
1.一种疤痕祛除与防控组合液的应用,其特征在于,该组合液用于拟制疤痕的产生和祛除疤痕,该组合液包括用于活血化瘀、融化分解疤体组织的混合液A、用于消毒消炎、收敛生肌的混合液B以及用于激活毛细血管恢复、促进胶原新生的混合液C;应用时,使用混合液A涂抹于疤痕上,一天涂抹1-3次,涂抹数天,当疤痕出现发黑、结痂等终点反应后,使用混合液B和混合液C交替涂抹,直至创面愈合;其中,
所述的混合液A,按重量份数计由以下各组分组成:
齐敦果酸20~40份、昆布20~40份、五倍子20~40份、金头蜈蚣5~10份、当归20~40份、鸦胆子油5~8份、硅酮5~10份、洋葱提取物7份;
所述的混合液B,按重量份数计有以下各组分组成:
积雪草提取物20~30份、七叶一枝花15~30份、昆布25~40份、五倍子10~15份、儿茶5~10份、白芨8~12份、当归5~10份、血竭3~6份;
所述的混合液B,按重量份数计有以下各组分组成:
ε-聚赖氨酸10~20份、溶菌酶20~40份、聚乙烯醇5~10份、醋酸氯已定3~5份。
2.根据权利要求1所述的疤痕祛除与防控组合液的应用,其特征在于,所述的混合液A的制备方法如下:
按照重量配比分别称取昆布、五倍子、金头蜈蚣和当归后,经粉碎、过筛、洗霉,然后倒入反应釜加入去离子水浸泡3小时,煮沸并恒温90℃,5小时,冷却、过滤,然后进行熬制3小时,冷却、过滤后得滤液,向滤液内加入齐敦果酸、鸦胆子油、硅酮和洋葱提取物,混合搅拌至完全溶解,将所得药液静置、再次过滤后,制得混合液A。
3.根据权利要求1所述的疤痕祛除与防控组合液的应用,其特征在于,所述的混合液B的制备方法如下:
按照重量配比分别称取积雪草提取物、七叶一枝花、昆布、五倍子、儿茶、白芨、当归及血竭,分别经粉碎、过筛、洗霉,倒入不锈钢容器,加入无水酒精,浸泡24×7小时,萃取液过滤,将所得药液静置、再次过滤后,制得混合液B。
4.根据权利要求1所述的疤痕祛除与防控组合液的应用,其特征在于,所述的混合液C的制备方法如下:
按照重量配比分别称取ε-聚赖氨酸、溶菌酶、聚乙烯醇和醋酸氯已定,倒入配置有搅拌机构的反应釜,开启搅拌,在倒入各组分时,边搅拌边加入原料,升温至50℃,恒温搅拌1小时,冷却将所得药液静置、过滤,制得混合液C。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010405123.9A CN111358940A (zh) | 2020-05-14 | 2020-05-14 | 一种疤痕祛除与防控组合液的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010405123.9A CN111358940A (zh) | 2020-05-14 | 2020-05-14 | 一种疤痕祛除与防控组合液的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111358940A true CN111358940A (zh) | 2020-07-03 |
Family
ID=71200032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010405123.9A Pending CN111358940A (zh) | 2020-05-14 | 2020-05-14 | 一种疤痕祛除与防控组合液的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111358940A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870301A (zh) * | 2021-01-26 | 2021-06-01 | 忧立舒医药科技(广东)有限公司 | 一种疤痕修复精华液及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1385197A (zh) * | 2002-04-12 | 2002-12-18 | 段川 | 伤口愈合膏 |
CN101797256A (zh) * | 2010-02-10 | 2010-08-11 | 中国人民解放军第二军医大学 | 齐墩果酸在制备治疗皮肤瘢痕药物中的应用 |
CN106728744A (zh) * | 2016-12-13 | 2017-05-31 | 广东科玮生物技术股份有限公司 | 一种促进伤口愈合防疤痕的组合物及其制剂 |
CN108066805A (zh) * | 2016-11-17 | 2018-05-25 | 中国科学院大连化学物理研究所 | 一种ε-聚赖氨酸仿生抑菌膜及其制备和应用 |
-
2020
- 2020-05-14 CN CN202010405123.9A patent/CN111358940A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1385197A (zh) * | 2002-04-12 | 2002-12-18 | 段川 | 伤口愈合膏 |
CN101797256A (zh) * | 2010-02-10 | 2010-08-11 | 中国人民解放军第二军医大学 | 齐墩果酸在制备治疗皮肤瘢痕药物中的应用 |
CN108066805A (zh) * | 2016-11-17 | 2018-05-25 | 中国科学院大连化学物理研究所 | 一种ε-聚赖氨酸仿生抑菌膜及其制备和应用 |
CN106728744A (zh) * | 2016-12-13 | 2017-05-31 | 广东科玮生物技术股份有限公司 | 一种促进伤口愈合防疤痕的组合物及其制剂 |
Non-Patent Citations (3)
Title |
---|
范晓清: "《中药美容小妙方》", 31 January 2008 * |
雷一鸣等: "《中华名医顽症绝症秘方大全》", 31 July 1999 * |
魏敏: "抗菌蛋白酶结合银敷料用于细菌生物膜感染的慢性伤口的效果研究", 《中国优秀硕士学位论文全文数据库(电子期刊)》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870301A (zh) * | 2021-01-26 | 2021-06-01 | 忧立舒医药科技(广东)有限公司 | 一种疤痕修复精华液及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109078165A (zh) | 一种用于女性私处护理的组合物及其制备方法与应用 | |
CN101310748A (zh) | 一种治疗烧烫伤的软膏 | |
CN105078864A (zh) | 一种祛痘面霜及其制备方法 | |
CN111358940A (zh) | 一种疤痕祛除与防控组合液的应用 | |
CN101693063A (zh) | 治疗烧烫伤及各种难愈性创面的中药制剂 | |
CN108837119A (zh) | 一种防治疤痕创面的修复精华液及其制备方法 | |
CN113509426A (zh) | 一种具有修复妊娠纹和肥胖纹的植物提取复合物及其制备方法和应用 | |
CN105078865A (zh) | 一种祛痘面膜及其制备方法 | |
CN111265642A (zh) | 一种祛痣、疣和汗管瘤的外用药物及其制备方法 | |
CN114028327B (zh) | 一种含依克多因和氯化锶口腔用中药抑菌凝胶及其制备、使用方法 | |
CN1053820C (zh) | 烧烫灵及其制备方法 | |
CN102106920B (zh) | 一种治疗烧烫伤的中药组合物及其用途 | |
CN113855605A (zh) | 一种花草原液的制备及使用方法 | |
CN111544514A (zh) | 一种用于治疗烧烫伤的中药膏剂及其制备方法 | |
CN110090264A (zh) | 一种组合使用修复疤痕产品配方及使用方法 | |
CN111544523A (zh) | 一种治疗皮肤溃烂的中药组合物及其应用 | |
CN1103226C (zh) | 一种治疗烧烫伤的药物 | |
CN104435271A (zh) | 一种治疗烧烫伤的中药组合物 | |
CN110624032A (zh) | 一种治疗烧烫伤的膏剂及其制备方法 | |
CN112704702B (zh) | 一种治疗头皮部银屑病的中药组合物及其制备方法 | |
CN112121119B (zh) | 一种治疗氢氟酸烧伤的药膏 | |
CN115844792B (zh) | 一种天然来源的祛痘微乳液及其制备方法 | |
KR101848180B1 (ko) | 화상증세 완화용 조성물의 제조방법 및 상기 제조방법으로 제조된 화상증세 완화용 조성물 | |
CN115463077A (zh) | 一种紧致修护精华液及其制备方法 | |
KR20010000043A (ko) | 피부질환 치료용 약제 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |
|
RJ01 | Rejection of invention patent application after publication |